-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 15, Jingfeng Pharmaceutical announced that its subsidiary Hainan Jinrui Pharmaceutical received the "Drug Supplementary Application Approval Notice" for gemcitabine hydrochloride for injection approved and issued by the State Food and Drug Administration.
The subsidiary gemcitabine hydrochloride for injection passed the quality and quality of generic drugs.
Consistency evaluation of efficacy
.
Gemcitabine hydrochloride for injection is mainly suitable for the treatment of locally advanced or metastatic non-small cell lung cancer or pancreatic cancer.
It can also be combined with paclitaxel for the treatment of relapsed, unresectable, locally recurring or metastatic breast after adjuvant/neoadjuvant chemotherapy Cancer
.
The original research product was developed by Eli Lilly and is now a category B product in the National Medical Insurance Catalog